Financhill
Sell
13

NONOF Quote, Financials, Valuation and Earnings

Last price:
$84.75
Seasonality move :
6.94%
Day range:
$79.15 - $86.50
52-week range:
$79.15 - $149.55
Dividend yield:
1.71%
P/E ratio:
27.46x
P/S ratio:
9.62x
P/B ratio:
20.85x
Volume:
124K
Avg. volume:
75.2K
1-year change:
-16.66%
Market cap:
$376.4B
Revenue:
$33.7B
EPS (TTM):
$3.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NONOF
Novo Nordisk AS
$10.5B -- 18.56% -- --
ASND
Ascendis Pharma AS
$74M -$1.57 -38% -18.13% $189.82
GLTO
Galecto
-- -$3.70 -- -51.46% --
GMAB
Genmab AS
$819.2M $0.33 29.9% 144.12% $36.56
LLY
Eli Lilly and
$12.1B $1.47 49.68% 124.93% $984.05
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NONOF
Novo Nordisk AS
$84.75 -- $376.4B 27.46x $0.52 1.71% 9.62x
ASND
Ascendis Pharma AS
$136.24 $189.82 $8.1B -- $0.00 0% 21.92x
GLTO
Galecto
$4.72 -- $6.2M -- $0.00 0% --
GMAB
Genmab AS
$20.31 $36.56 $12.9B 19.29x $0.00 0% 4.58x
LLY
Eli Lilly and
$767.76 $984.05 $728.8B 83.00x $1.30 0.68% 16.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NONOF
Novo Nordisk AS
32.1% 0.420 1.64% 0.74x
ASND
Ascendis Pharma AS
114.08% 2.670 9.87% 0.81x
GLTO
Galecto
-- 2.093 -- --
GMAB
Genmab AS
-- 0.743 -- 5.15x
LLY
Eli Lilly and
68.61% 0.948 3.9% 0.63x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NONOF
Novo Nordisk AS
$8.8B $5B 65.63% 88.95% 49.37% $4.7B
ASND
Ascendis Pharma AS
$51.3M -$106.4M -89.94% -- -125.93% -$110.6M
GLTO
Galecto
-- -$3.8M -- -- -- -$3.7M
GMAB
Genmab AS
$776.2M $312.3M 14.86% 14.86% 31.35% $301.5M
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M

Novo Nordisk AS vs. Competitors

  • Which has Higher Returns NONOF or ASND?

    Ascendis Pharma AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -171.53%. Novo Nordisk AS's return on equity of 88.95% beat Ascendis Pharma AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.14% $0.90 $26.6B
    ASND
    Ascendis Pharma AS
    80.63% -$1.89 $772.2M
  • What do Analysts Say About NONOF or ASND?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 12.33%. On the other hand Ascendis Pharma AS has an analysts' consensus of $189.82 which suggests that it could grow by 39.33%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    ASND
    Ascendis Pharma AS
    11 1 0
  • Is NONOF or ASND More Risky?

    Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.529%.

  • Which is a Better Dividend Stock NONOF or ASND?

    Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or ASND?

    Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.46x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.62x versus 21.92x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    9.62x 27.46x $10.5B $4B
    ASND
    Ascendis Pharma AS
    21.92x -- $63.6M -$109.1M
  • Which has Higher Returns NONOF or GLTO?

    Galecto has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.14% $0.90 $26.6B
    GLTO
    Galecto
    -- -$3.39 --
  • What do Analysts Say About NONOF or GLTO?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 12.33%. On the other hand Galecto has an analysts' consensus of -- which suggests that it could grow by 111.86%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GLTO
    Galecto
    0 0 0
  • Is NONOF or GLTO More Risky?

    Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NONOF or GLTO?

    Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GLTO?

    Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Galecto's net income of -$3.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.46x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.62x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    9.62x 27.46x $10.5B $4B
    GLTO
    Galecto
    -- -- -- -$3.9M
  • Which has Higher Returns NONOF or GMAB?

    Genmab AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 22.85%. Novo Nordisk AS's return on equity of 88.95% beat Genmab AS's return on equity of 14.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.14% $0.90 $26.6B
    GMAB
    Genmab AS
    95.07% $0.29 $4.8B
  • What do Analysts Say About NONOF or GMAB?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 12.33%. On the other hand Genmab AS has an analysts' consensus of $36.56 which suggests that it could grow by 80.03%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GMAB
    Genmab AS
    2 5 0
  • Is NONOF or GMAB More Risky?

    Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.991%.

  • Which is a Better Dividend Stock NONOF or GMAB?

    Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GMAB?

    Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Genmab AS quarterly revenues of $816.4M. Novo Nordisk AS's net income of $4B is higher than Genmab AS's net income of $186.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.46x while Genmab AS's PE ratio is 19.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.62x versus 4.58x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    9.62x 27.46x $10.5B $4B
    GMAB
    Genmab AS
    4.58x 19.29x $816.4M $186.6M
  • Which has Higher Returns NONOF or LLY?

    Eli Lilly and has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 8.48%. Novo Nordisk AS's return on equity of 88.95% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.14% $0.90 $26.6B
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About NONOF or LLY?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 12.33%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than Novo Nordisk AS, analysts believe Eli Lilly and is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    LLY
    Eli Lilly and
    15 6 0
  • Is NONOF or LLY More Risky?

    Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

  • Which is a Better Dividend Stock NONOF or LLY?

    Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or LLY?

    Novo Nordisk AS quarterly revenues are $10.5B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Novo Nordisk AS's net income of $4B is higher than Eli Lilly and's net income of $970.3M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.46x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.62x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    9.62x 27.46x $10.5B $4B
    LLY
    Eli Lilly and
    16.99x 83.00x $11.4B $970.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 5.45% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 7.5% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 2.01% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock